What are the relative contraindications to combined oral contraceptive pills in a woman older than 40 years?

Relative Contraindications to Combined Oral Contraceptives in Women Over 40

In women over 40, the key relative contraindications to combined oral contraceptives include: smoking <15 cigarettes daily, controlled hypertension (SBP 140-159 or DBP 90-99 mmHg), history of VTE without ongoing risk factors, superficial venous thrombosis, and multiple atherosclerotic risk factors. 1

Age-Specific Cardiovascular Risk Considerations

Age over 40 itself is NOT a contraindication to COCs, but age amplifies other cardiovascular risk factors. The critical distinction lies in whether additional risk factors are present:

Smoking Status (Most Important Age-Related Factor)

• Age ≥35 + smoking <15 cigarettes/day = Category 3 (relative contraindication) 1
• Age ≥35 + smoking ≥15 cigarettes/day = Category 4 (absolute contraindication)
• The relative risk of myocardial infarction and stroke increases substantially with age, making even light smoking problematic after 35 2

Blood Pressure

• SBP 140-159 mmHg or DBP 90-99 mmHg = Category 3 1
• Adequately controlled hypertension on treatment (in women <35 without other risk factors) may be Category 3, but requires careful clinical judgment 2
• Blood pressure measurement is mandatory before prescribing COCs at any age 2

Venous Thromboembolic Risk Factors

History of VTE without current risk factors = Category 3 1

• Superficial venous thrombosis = Category 3
• The baseline VTE risk increases with age independent of COC use, making this particularly relevant after 40 2

Metabolic and Atherosclerotic Risk

Multiple risk factors for atherosclerosis = Category 3 1

These include:

• Older age (>40)
• Smoking
• Diabetes mellitus
• Hypertension
• Dyslipidemia (low HDL, high LDL, high triglycerides)

The cumulative effect of multiple risk factors creates exponential rather than additive risk, making COCs inadvisable even when individual factors might be mild 1.

Diabetes-Related Considerations

For women over 40 with diabetes:

• Diabetes with duration ≥20 years = Category 3 or 4 (depending on severity of complications) 1
• Diabetes with nephropathy, retinopathy, neuropathy, or other vascular disease = Category 4 (absolute contraindication)
• Type 1 diabetes without complications or risk factors: COCs may be considered 2
• Type 2 diabetes: progestin-only methods preferred regardless of complications 2

Migraine Considerations

• Migraine with aura = Category 4 (absolute contraindication) at any age 1
• Migraine without aura in women ≥35 = Category 3 (relative contraindication)
• The stroke risk with migraine plus COCs increases significantly with age 2

Cancer History

Past breast cancer with no evidence of disease for 5 years = Category 3 1

• Current breast cancer = Category 4 (absolute)

Postpartum Period (Relevant for Older Mothers)

• Breastfeeding 21-29 days postpartum = Category 3 1
• Breastfeeding 30-42 days postpartum with other VTE risk factors = Category 3
• Non-breastfeeding 21-42 days postpartum with VTE risk factors = Category 3

Critical Clinical Pitfalls

1. Don't dismiss "light" smoking: Even <15 cigarettes/day after age 35 is a relative contraindication 2

2. Multiple mild risk factors compound: A 42-year-old woman who smokes 10 cigarettes daily, has borderline hypertension (SBP 145), and BMI 32 has multiple Category 3 conditions—COCs should be avoided 1

3. Controlled hypertension is still a concern: "Adequately controlled" hypertension remains Category 3 in women over 35, especially with other risk factors 2

4. All routes of combined hormonal contraception share contraindications: Patches and vaginal rings have the same contraindications as oral COCs 2

Recommended Alternatives for Women Over 40 with Relative Contraindications

When Category 3 conditions exist:

• Progestin-only pills (POPs) 2, 3
• Levonorgestrel IUD 2
• Etonogestrel implant 2
• Copper IUD (non-hormonal) 2

These methods avoid the estrogen-related cardiovascular risks that make COCs problematic in women over 40 with risk factors 3, 4.

Evidence Quality Note

The 2024 American Academy of Dermatology guidelines 1 provide the most recent comprehensive summary of contraindications based on the CDC's US Medical Eligibility Criteria. The French Society of Endocrinology 2012 guidelines [2-2] offer more granular risk stratification for specific conditions, though slightly older. Both align on core recommendations regarding age-related cardiovascular risk.